Prior exposure to ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL) has been associated with improved efficacy of chimeric antigen receptor T-cell therapy (CAR-T).[1] Specifically, it is the preparation brexucabtagene autoleucel.[1] The study showed that patients previously treated with ibrutinib did better after CAR-T therapy in this rare lymphoma.[1] Ibrutinib is registered for the treatment of relapsed or refractory forms of MCL in adult patients with at least one prior treatment.[4] Brexucel, which is used in MCL, is associated with a higher risk of neurotoxicity compared to other indications.[1] These findings come from an analysis of third-line MCL patients.[1]